1. A randomized, double‐blind phase I/IIa study of intranasal glutathione in Parkinson's disease. Issue 12 (31st July 2015) Authors: Mischley, Laurie K.; Leverenz, James B.; Lau, Richard C.; Polissar, Nayak L.; Neradilek, Moni B.; Samii, Ali; Standish, Leanna J. Journal: Movement disorders Issue: Volume 30:Issue 12(2015) Page Start: 1696 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study. Issue 4 (August 2018) Authors: Guo, Michael Y.; Etminan, Mahyar; Procyshyn, Ric M.; Kim, David D.; Samii, Ali; Kezouh, Abbas; Carleton, Bruce C. Journal: Journal of clinical psychopharmacology Issue: Volume 38:Issue 4(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Issue 7407 (17th July 2003) Authors: Etminan, Mahyar; Gill, Sudeep; Samii, Ali Journal: BMJ Issue: Volume 327:Issue 7407(2003) Page Start: 128 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effects of β2‐Adrenergic Agonists on Risk of Parkinson's Disease in COPD: A Population‐Based Study. Issue 5 (1st April 2020) Authors: Chen, Wenjia; Sadatsafavi, Mohsen; Tavakoli, Hamid; Samii, Ali; Etminan, Mahyar Journal: Pharmacotherapy Issue: Volume 40:Issue 5(2020) Page Start: 408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Electroconvulsive therapy for depression in Parkinson's disease: systematic review of evidence and recommendations. (April 2016) Authors: Borisovskaya, Anna; Bryson, William Culbertson; Buchholz, Jonathan; Samii, Ali; Borson, Soo Journal: Neurodegenerative disease management Issue: Volume 6:Number 2(2016) Page Start: 161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. Issue 1 (17th May 2021) Authors: Lai, Dongbing; Alipanahi, Babak; Fontanillas, Pierre; Schwantes‐An, Tae‐Hwi; Aasly, Jan; Alcalay, Roy N.; Beecham, Gary W.; Berg, Daniela; Bressman, Susan; Brice, Alexis; Brockman, Kathrin; Clark, Lorraine; Cookson, Mark; Das, Sayantan; Van Deerlin, Vivianna; Follett, Jordan; Farrer, Matthew J.; ... Journal: Annals of neurology Issue: Volume 90:Issue 1(2021) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk. Issue 9 (September 2015) Authors: Costa-Mallen, Paola; Zabetian, Cyrus P.; Agarwal, Pinky; Hu, Shu-Ching; Yearout, Dora; Samii, Ali; Leverenz, James B.; Roberts, John W.; Checkoway, Harvey Journal: Parkinsonism & related disorders Issue: Volume 21:Issue 9(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Head injury and risk of Parkinson disease: A systematic review and meta‐analysis. Issue 9 (22nd April 2013) Authors: Jafari, Siavash; Etminan, Mahyar; Aminzadeh, Farhad; Samii, Ali Journal: Movement disorders Issue: Volume 28:Issue 9(2013) Page Start: 1222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Intraventricular Baclofen Following Deep Brain Stimulation in a Child with Refractory Status Dystonicus. Issue 3 (19th March 2021) Authors: Mingbunjerdsuk, Dararat; Blume, Heidi; Browd, Samuel; Samii, Ali Journal: Movement disorders clinical practice Issue: Volume 8:Issue 3(2021) Page Start: 456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington's disease (HD). (12th September 2022) Authors: Furr Stimming, Erin; Sung, Victor; Testa, Claudia; Kostyk, Sandra; Ross, Christopher A; Samii, Ali; Geschwind, Michael D; Hall, Deborah; Dayalu, Praveen; Lonser, Russell; Elder, Brad; Larson, Paul S; Cooper, David L; Clarkin, Marcie; Ali, Talaha M; Dolmetsch, Ricardo E Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93(2022)Supplement 1 Page Start: A95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗